A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects

Trial Profile

A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 May 2017

At a glance

  • Drugs Cabotegravir (Primary) ; Rilpivirine (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LATTE
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Results assessing long term safety and efficacy of CAB and RPV, presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 29 May 2014 Planned End Date changed from 1 Dec 2016 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top